EDAP TMS SA announced the successful treatment of the first patient in its phase I/II PULS Trial, which is investigating the use of High Intensity Focused Ultrasound (HIFU) technology for pancreatic ...
Dermatology is undergoing a quiet but powerful transformation. More and more decisions are being shaped by technology-driven ...
AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored ...
LYON, France, October 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the ...
Semi-Live Focal One Procedure to be Conducted on August 15th at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today ...
High-intensity focused ultrasound (HIFU) is a noninvasive way to destroy tissue or stop it from working. It was approved by the U.S. Food and Drug Administration for prostate ablation in 2015, but the ...
Medical professionals have described the introduction of High-Intensity Focused Ultrasound (HIFU) technology for treating fibroids in Nigeria as a significant feat. The deployment of the technology by ...
John Wayne Cancer Institute (JWCI) at Providence Saint John’s Health Center is once again breaking new ground to benefit cancer patients. It has become the first medical center in the country to ...
CHARLOTTE, NC / ACCESSWIRE / April 16, 2024 / HIFU Prostate Services, LLC (HPS), the leading provider of non-invasive prostate cancer treatments, using High Intensity Focused Ultrasound (HIFU), is ...
The appointment of Joshua H. Levine to the Board of Directors brings significant executive experience and a proven track record of enhancing shareholder value in the medical technology sector. The ...
AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback